Bacil Pharma Statistics
Total Valuation
Bacil Pharma has a market cap or net worth of INR 447.67 million. The enterprise value is 420.74 million.
| Market Cap | 447.67M |
| Enterprise Value | 420.74M |
Important Dates
The next estimated earnings date is Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Bacil Pharma has 14.35 million shares outstanding. The number of shares has increased by 34.82% in one year.
| Current Share Class | 14.35M |
| Shares Outstanding | 14.35M |
| Shares Change (YoY) | +34.82% |
| Shares Change (QoQ) | +78.61% |
| Owned by Insiders (%) | 9.27% |
| Owned by Institutions (%) | n/a |
| Float | 12.20M |
Valuation Ratios
The trailing PE ratio is 22.33.
| PE Ratio | 22.33 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.76 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 38.01 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -1.48% |
| Return on Capital Employed (ROCE) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | 5.53M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Bacil Pharma has paid 2.28 million in taxes.
| Income Tax | 2.28M |
| Effective Tax Rate | 17.10% |
Stock Price Statistics
The stock price has decreased by -22.25% in the last 52 weeks. The beta is 0.50, so Bacil Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.50 |
| 52-Week Price Change | -22.25% |
| 50-Day Moving Average | 39.51 |
| 200-Day Moving Average | 41.34 |
| Relative Strength Index (RSI) | 27.31 |
| Average Volume (20 Days) | 38,640 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.18M |
| Pretax Income | 13.35M |
| Net Income | 11.07M |
| EBITDA | -3.18M |
| EBIT | -3.18M |
| Earnings Per Share (EPS) | 1.40 |
Balance Sheet
The company has 28.57 million in cash and 1.64 million in debt, giving a net cash position of 26.93 million or 1.88 per share.
| Cash & Cash Equivalents | 28.57M |
| Total Debt | 1.64M |
| Net Cash | 26.93M |
| Net Cash Per Share | 1.88 |
| Equity (Book Value) | 254.31M |
| Book Value Per Share | 32.60 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bacil Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.82% |
| Shareholder Yield | -34.82% |
| Earnings Yield | 2.47% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |